Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative cardiovascular (CV) risk of SGLT2 inhibitors (canagliflozin and empagliflozin) and liraglutide in patients with type 2 diabetes

Trial Profile

Comparative cardiovascular (CV) risk of SGLT2 inhibitors (canagliflozin and empagliflozin) and liraglutide in patients with type 2 diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Canagliflozin (Primary) ; Empagliflozin (Primary) ; Liraglutide (Primary)
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top